Cipla

1,366.00

-7.30

(-0.53%)

Market Cap

1,10,351.67 Cr

PE Ratio

33.22

Volume

16,81,155.00

Day High - Low

1,373.00 - 1,347.70

52W High-Low

1,673.00 - 1,165.70

compare with

Sun Pharmaceutical

1,840.00 (-1.13%)

Divis Laboratories

9,322.00 (-1.23%)

Torrent Pharmaceuticals

4,965.50 (+0.72%)

Zydus Life Science

1,119.10 (+0.12%)

Laurus Labs

1,969.00 (+1.23%)

Key Fundamentals

Market Cap

1,10,351.67 Cr

EPS

48.03

PE Ratio

33.22

PB Ratio

3.24

Book Value

426.21

EBITDA

6,764.90

Dividend Yield

0.94 %

Industry

Healthcare

Sector

Pharmaceuticals

Return on Equity

11.21

Debt to Equity

0.02

Actual

Company News

View All News

Macquarie keeps Cipla at Outperform, target ₹1,6751 day ago

Macquarie maintains an Outperform rating on Cipla with a target price of ₹1,675, noting key prior observations at the Pithampur plant appear addressed, though five repeat observations remain.

InvaGen signs exclusive deal for Keytruda biosimilar QL21079 days ago

Cipla's subsidiary InvaGen Pharmaceuticals has entered an exclusive agreement with Qilu Pharmaceutical for the biosimilar QL2107, a Keytruda biosimilar.

Cipla amalgamates with Inzpera Healthsciences

9 days ago

Cipla Limited has notified stakeholders of the NCLT order approving its scheme of amalgamation with Inzpera Healthsciences. Shareholders and creditors have 30 days to submit representations.

Peer Comparison Compare Peers on Screener

Competitors	LTP	Market Cap (₹ Cr.)	P/E Ratio	Revenue (₹ Cr.)	YoY Revenue Growth %	Net Profit (₹ Cr.)	YoY Profit Growth %	RSI
Sun Pharmaceutical	1,840.00	#1 4,41,477.63	36.91	#1 61,673.90	12.69	#1 11,565	26.53	34.00
Divis Laboratories	9,322.00	2,47,469.81	85.36	11,067.00	13.95	2,568	65.50	63.65
Torrent Pharmaceuticals	4,965.50	1,88,871.66	86.95	13,886.20	20.34	2,138	3.28	52.16
Zydus Life Science	1,119.10	1,12,607.65	24.28	27,657.90	17.64	5,026	-34.90	45.64
Cipla	1,366.00	#5 1,10,351.67	#5 33.22	#4 29,044.60	#10 2.24	#5 3,870	#9 -39.18	35.27
Laurus Labs	1,969.00	1,06,297.76	95.94	6,867.80	22.01	890	#1 123.93	68.28
Dr Reddys Laboratories	1,165.50	97,280.68	29.91	35,058.60	3.90	4,158	-69.10	47.72
Aurobindo Pharma	1,679.80	96,651.98	25.88	34,145.20	5.56	3,503	25.21	57.04
Lupin	2,095.00	95,790.22	#1 17.09	29,038.90	#1 26.75	5,356	16.00	28.17
Mankind Pharma	2,280.00	94,163.08	44.87	14,636.40	14.85	1,938	29.13	37.57

Automatic Screeners on ScanX

Growth Rate

Revenue Growth

2.24 %

Net Income Growth

-26.86 %

Cash Flow Change

-21.28 %

ROE

-33.71 %

ROCE

-31.02 %

EBITDA Margin (Avg.)

-17.18 %

Corporate Action

Record Date	Corporate Action	Information	Announcement Day	LTP at Annoucement	LTP at Record Day
11 Aug 2021	Dividend	₹ 5.00 /share	09 Aug 2021	898.60	912.60
10 Aug 2022	Dividend	₹ 5.00 /share	08 Aug 2022	937.55	1,029.55
26 Aug 2022	Annual General Meeting	NA	26 Aug 2022	955.10	1,025.45
21 Jul 2023	Dividend	₹ 8.50 /share	21 Jul 2023	943.95	1,056.20
02 Aug 2024	Dividend	₹ 13.00 /share	02 Aug 2024	1,358.80	1,546.15
20 Aug 2024	Annual General Meeting	NA	20 Aug 2024	1,358.80	1,575.50
29 Oct 2024	Quarterly Result Announcement	NA	29 Oct 2024	1,654.10	1,503.50
28 Jan 2025	Quarterly Result Announcement	NA	28 Jan 2025	1,510.25	1,395.90
13 May 2025	Quarterly Result Announcement	NA	13 May 2025	1,415.25	1,511.60
27 Jun 2025	Dividend	₹ 13.00 /share	27 Jun 2025	1,511.60	1,512.75
27 Jun 2025	Dividend	₹ 3.00 /share	27 Jun 2025	1,511.60	1,512.75
16 Jul 2025	Annual General Meeting	NA	16 Jul 2025	1,511.60	1,490.90
25 Jul 2025	Quarterly Result Announcement	NA	25 Jul 2025	1,505.30	1,487.25
30 Oct 2025	Quarterly Result Announcement	NA	30 Oct 2025	1,527.10	1,581.10
23 Jan 2026	Quarterly Result Announcement	NA	23 Jan 2026	1,512.50	1,370.40
13 May 2026	Quarterly Result Announcement	NA	13 May 2026	1,223.05	1,292.30
05 Jun 2026	Dividend	₹ 13.00 /share	05 Jun 2026	1,292.30	1,398.70
25 Jun 2026	Annual General Meeting	NA	25 Jun 2026	1,292.30	1,437.90
23 Jul 2026	Quarterly Result Announcement	NA	23 Jul 2026	1,433.10	1,415.10

Funding House	Current Holding %	1M Change	1M Change %	3M Change %
Abakkus Large & Mid Cap Fund Direct-Growth	2.04%	63228	2.04%	2.04%
NJ Value Fund Direct-Growth	1.28%	18298	1.28%	1.28%
SBI Nifty100 Low Volatility 30 Index Fund Direct-Growth	0.00%	-13694	-3.38%	-3.52%
The Wealth Company Large & Mid Cap Fund Direct-Growth	0.00%	-13000	-1.88%	-1.94%
Unifi Dynamic Asset Allocation Fund Direct-Growth	0.29%	11050	0.09%	0.10%
UTI Nifty 500 Index Fund Direct-Growth	0.40%	3097	0.40%	0.40%
Parag Parikh Large Cap Fund Direct-Growth	0.59%	1659	-0.02%	-0.02%
AlphaGrep Multi Asset Allocation Fund Direct-Growth	0.33%	1404	0.23%	0.33%
Bajaj Finserv Equity Savings Fund Direct-Growth	0.20%	-1275	-0.46%	-0.53%
Capitalmind Arbitrage Fund Direct-Growth	0.00%	-850	-0.56%	-0.59%
Groww Arbitrage Fund Direct-Growth	0.00%	-850	-0.14%	0.00%
Axis Nifty50 Equal Weight Index Fund Direct-Growth	1.92%	-831	-0.08%	1.92%
JioBlackRock Sector Rotation Fund Direct-Growth	0.65%	778	0.02%	-0.05%
DSP Nifty Healthcare Index Fund Direct-Growth	6.82%	658	-0.38%	-0.76%
HDFC BSE India Sector Leaders Index Fund Direct-Growth	0.98%	-470	-0.02%	-0.05%
Nippon India BSE Sensex Next 30 Index Fund Direct-Growth	2.99%	399	-0.12%	-0.21%
UTI Nifty500 Shariah Index Fund Direct-Growth	1.29%	-286	-0.12%	-0.19%
Nippon India Nifty India Manufacturing Index Fund Direct-Growth	1.83%	182	-0.12%	-0.15%
Zerodha Nifty 50 Index Fund Direct-Growth	0.72%	171	-0.02%	-0.03%
JioBlackRock Nifty 50 Index Fund Direct-Growth	0.72%	-156	-0.02%	-0.03%
Groww Nifty 50 Index Fund Direct-Growth	0.72%	76	-0.02%	-0.03%
Axis BSE India Sector Leaders Index Fund Direct-Growth	0.98%	-76	-0.02%	-0.05%
Zerodha Life Cycle Fund 2041 Direct-Growth	0.24%	69	0.00%	0.24%
Bandhan BSE India Sector Leaders Index Fund Direct-Growth	0.98%	-65	-0.03%	-0.05%
Zerodha Life Cycle Fund 2036 Direct-Growth	0.19%	63	0.00%	0.19%

Technical Indicators

RSI(14)

Neutral

36.94

ATR(14)

Less Volatile

22.33

STOCH(9,6)

Oversold

16.21

STOCH RSI(14)

Oversold

12.30

MACD(12,26)

Bearish

-5.36

ADX(14)

Weak Trend

23.30

UO(9)

Bearish

43.85

ROC(12)

Downtrend And Accelerating

-3.42

WillR(14)

Oversold

-87.12

About Cipla

Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective,...more

Website

https://www.cipla.com

Chairperson NameY K Hamied

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104

Cipla

Company News

Peer Comparison Compare Peers on Screener

Automatic Screeners on ScanX

Corporate Action

Mutual Fund Holdings

Technical Indicators

About Cipla